Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of two leukemia cell lines K562 and Lucena-1.

ABSTRACT: The Lucena 1 cell line, derived from the K562 human chronic myeloid leukemia cell line, shows multidrug resistance (MDR) due to selective pressure from vincristine supplementation. A proteomic analysis comparing K562 and Lucena 1 revealed qualitative differences. The ATP-dependent efflux pump, Translocase ABCB1, which is crucial for drug resistance, was a focus. Tubulin analysis identified an exclusive isoform, Tubulin beta 8B, in Lucena 1, potentially affecting resistance mechanisms. Additionally, Rap1A and Krit1 association in cytoskeletal regulation, along with STAT1 presence linked to urea cycle and tumor development, shed light on Lucena 1's unique biology. Increased Carbonic anhydrase I expression suggested a role in pH regulation. COP9, a tumor suppressor targeting p53, was discovered, further highlighting Lucena 1's complex molecular landscape. This study provides insights into the MDR phenotype and its multifactorial consequences in cellular pathways.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Emidio Beraldo Neto

PROVIDER: PXD053987 | JPOST Repository | Tue Aug 13 00:00:00 BST 2024

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1.%20protein_lucena.html	Other
	2.%20protein_k562.html	Other
	K562_1_RA2_01_1098.d.zip	Other
	K562_2_RA2_01_1099.d.zip	Other
	Lucena_1_RA3_01_1101.d.zip	Other

Items per page:

1 - 5 of 6

Similar Datasets

Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance

Project description:Multidrug resistance (MDR) frequently develops in cancer patients exposed to chemotherapeutic agents and is usually brought about by over-expression of P-glycoprotein (P-gp) which acts as a drug efflux pump. MiRNAome profiling using next-generation sequencing identified differentially expressed microRNAs (miRs) between parental K562 cells and MDR K562 cells (K562/ADM) induced by chronic adriamycin treatment. MiRNAome profiling in untreated K562 cells and K562 cells exposed to long-term adriamycin treatment

2013-10-29 | E-GEOD-51774 | biostudies-arrayexpress

4da0d358-1544-4812-a29a-6b30a85f5b0c - samples

Project description:K562 cell line has been treated with two different HSP90 inhibtors. After resistance clones emerged, they have been genetically characterized using WES in comparison to the parental K562 cell line.

| EGAD00001009051 | EGA

Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance

2013-10-29 | GSE51774 | GEO

Expression data for human chronic myeloid leukemia K562 cell line (KS) and adriamycin induced multidrug-resistant K562/ADR (KA) cell line before and after treatment with hypomethylating agent decitabine

Project description:To explore the mechanisim and signaling pathway of hypomethylating agent decitabine in reversing P-glycoprotein(P-gp) induced multidrug resistance, we used adriamycin to treat drug sensitive human chronic myeloid leukemia K562 cells(KS) and successfully induced multidrug-resistant K562/ADR (KA) cells that higher expression of drug efflux pump P-gp. Gene expression profile was used to analysis the difference gene expression before and after treated with decitabine in both KS and KA cells.

2018-03-01 | GSE93942 | GEO

Exosomes released by imatinib-resistant K562 cells carry specific membrane markers and increase survival of imatinib-sensitive cells in the presence of imatinib.

Project description:Chronic myeloid leukemia is a malignant hematopoietic disorder distinguished by a presence of BCR-ABL fused oncogene with constitutive kinase activity. Although targeted therapy by tyrosine kinase inhibitors (TKI) markedly improved patient´s survival and quality of life, development of drug resistance remains a critical issue for a subset of patients. The most common mechanism of TKI resistance in CML patients is a mutation in BCR-ABL gene which makes oncogenic Bcr-Abl protein insensitive to TKI therapy. Mutation independent mechanisms of TKI resistance are less elucidated, but exosomes, extracellular vesicles excreted from normal and tumor cells were recently linked with cancer progression and drug resistance. We used an imatinib-sensitive CML cell line K562 and derived an imatinib-resistant subline K562IR by prolonged cultivation of cells in presence of imatinib. We demonstrated that exosomes isolated from K562IR cells are internalized by K562 cells and increase their survival in presence of 2µM imatinib. To characterize the exosomal cargo and to identify resistance-associated marker proteins, we performed a deep proteomic analysis of exosomes from both cell sublines using label free quantification (LFQ). In total, we identified over 3000 exosomal proteins including 31 proteins differentially abundant in exosomes derived from K562IR cells. Among the differential proteins were three massively upregulated membrane proteins in K562IR exosomes with surface localization: IFITM3, CD146, CD36. We verified the massive upregulation of the three proteins in K562IR exosomes and also in K562IR cells. Using flow cytometry, we further demonstrated potential of CD146 as cell surface marker associated with imatinib resistance in K562 cells.

2024-10-24 | PXD019283 | Pride

Genome wide DNA methylation analysis of leukemia and reprogrammed leukemia cells (sequencing)

Project description:We analyzed the methylation pattern of a well characterized leukemia cell line, named K562. Furthermore, we decided to investigate how the malignant epiegenome change during the reprogramming process We used RRBS analysis to investigate the methylation pattern in leukemia and reprogrammed leukemia (LiPS).We show that the erasure of the epigenetic aberrancies have functional consequences on leukemia phenotype

2012-10-01 | E-GEOD-33230 | biostudies-arrayexpress

Changes in Gene Expression Profile in two Multidrug Resistant Cell Lines derived from a same Drug Sensitive Cell line

Project description:Resistance to chemotherapy is one of the most relevant aspects of treatment failure in cancer. Cell lines are used as models to study resistance. We analyze the transcriptional profile of two multidrug resistant (MDR) cell lines (Lucena 1 and FEPS) derived from the same drug-sensitive cell K562. Microarray data identified 130 differentially expressed genes (DEG) between K562 vs Lucena, 1,932 between K562 vs FEPS, and 1,211 between Lucena 1 versus FEPS. The NOTCH pathway was affected in FEPS with overexpression of NOTCH2 and HEY1. The highly overexpressed gene in MDR cell was ABCB1, and both presented the ABCB1 promoter unmethylated. Gene expression profiles were obtained with the GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix, Singapore) according to the manufacturer´s instructions; all hybridization experiments were carried out in duplicate. The following samples were analyzed: human K562 cell line RNA from cells grown without drugs; human Lucena 1 cell line RNA from cells grown in medium with vincristine (Lucena 1+VCR); Lucena 1 cell line RNA from cells grown in medium without drugs (Lucena 1-VCR); human FEPS cell line RNA from cells grown in medium with daunorubicin (FEPS +DNR), and FEPS cell line RNA from cells grown in medium without drugs (FEPS -DNR).Comparisons of microarray expression data were carried out between K562 vs Lucena 1 grown in medium without vincristine; K562 vs FEPS grown in medium without daunorubicin; Lucena 1 grown in medium without vincristine vs FEPS grown in medium without daunorubicin. Additionally, we compared expression profiles of each multidrug resistant cell line (Lucena 1 and FEPS) grown in different conditions: Lucena 1 grown in medium without vincristine vs Lucena 1 grown in medium with vincristine, and FEPS grown in medium without daunorubicin vs FEPS grown in medium with daunorubicin.

2015-01-01 | E-GEOD-57470 | biostudies-arrayexpress

Homo sapiens

Project description:human leukemia cell line K562 offspring acquring imatinib resistance(K562-r) : Control vs. Drug treated

| PRJNA131951 | ENA

Genome wide DNA methylation analysis of leukemia and reprogrammed leukemia cells (gene expression)

Project description:We analyzed the methylation pattern of a well characterized leukemia cell line, named K562. Furthermore, we decided to investigate how the malignant epiegenome change during the reprogramming process We used Affymatrix expression microarrays analysis to investigate the relation between expression and methylation in leukemia and reprogrammed leukemia (LiPS). We show that the erasure of the epigenetic aberrancies have functional consequences on leukemia phenotype

2012-10-01 | E-GEOD-33226 | biostudies-arrayexpress

Dasatinib Resistant K562 cell lines

Project description:A project to explore the acquisition of drug resistance mechanisms in a K562 erythroblastic leukemia cell line, with induced resistance to the tyrosine kinase inhibitor, dasatinib.

2023-08-08 | GSE239677 | GEO